低剂量阿立哌唑对服用奥氮平的精神分裂症患者代谢及生活质量的影响

发布时间：2018-01-10 13:34

  本文关键词：低剂量阿立哌唑对服用奥氮平的精神分裂症患者代谢及生活质量的影响　出处：《中国新药与临床杂志》2015年12期 　论文类型：期刊论文

  更多相关文章： 精神分裂症 奥氮平 阿立哌唑 代谢综合征 生活质量

【摘要】：目的评估低剂量阿立哌唑合并奥氮平治疗精神分裂症对患者安全性、代谢和生活质量的影响。方法筛选符合入组条件的服用固定剂量奥氮平10~20 mg·d~(-1)的患者120例,随机分为阿立哌唑组[阿立哌唑10 mg·d~(-1)+奥氮平(15.12±1.95)mg·d~(-1)]和对照组[奥氮平(14.95±2.08)mg·d~(-1)]各60例,进行为期12周的非盲、平行对照研究。阿立哌唑10 mg顿服,奥氮平维持入组时剂量直至整个研究结束。分别于基线和4、8、12周末进行生命体征测量、体重变化和体重指数(BMI)测量和计算;在基线和12周末进行阳性与阴性症状量表(PANSS)、临床总体印象量表-疾病严重程度(CGI-S)评估和精神分裂症患者生活质量量表(SQLS)评估,同时进行血糖、血脂、血压等代谢和生物学安全性指标检测和不良事件观察。结果阿立哌唑组体重和BMI各时点与基线比较显著下降(P0.05),其代谢指标在治疗过程中无显著变化(P0.05),空腹血糖、三酰甘油、总胆固醇与对照组比较有显著差异(P0.05)。治疗12周末,两组PANSS总分和CGI-S分治疗前后组内比较均有显著差异(P0.05),且两组间无显著差异(P0.05);阿立哌唑组SQLS的3个分量表分与基线比较均无显著差异(P0.05),而对照组的心理社会分量表分高于基线(P0.05),两组间比较有显著差异(P=0.017)。两组药物不良事件均为轻或中度,多数能耐受,发生率相当(P0.05)。结论使用奥氮平的稳定期精神分裂症患者,短期内合用低剂量阿立哌唑10 mg·d~(-1)治疗,能明显改善血糖、血脂等代谢参数,且有明显降低体重的趋势,不良事件发生率较低,对精神分裂症患者的生活质量无明显影响。
[Abstract]:Objective to evaluate the safety of low dose aripiprazole combined with olanzapine in the treatment of schizophrenia. Effects of metabolism and quality of life. Methods 120 patients who were treated with fixed dose of olanzapine 1020 mg 路dan-1) were randomly divided into two groups: aripiprazole group. [Aripiprazole 10 mg 路dan-1) olanzapine 15.12 卤1.95 mg 路dan-1] and control group. [Sixty patients with olanzapine (14.95 卤2.08mg 路dan-1) were given a 12-week, non-blind, parallel controlled study. Aripiprazole was given orally for 10 mg. The dose of olanzapine was maintained until the end of the whole study. Vital signs, body mass change and body mass index (BMIs) were measured and calculated at baseline and at the end of 12 weeks. The positive and negative symptom scale (PANSS) was carried out at baseline and at the end of 12 weeks. General impression scale (GIM)-severity of disease (CGI-S) and schizophrenia quality of life (QOL) were evaluated, and blood glucose and blood lipid were also evaluated. Results the body weight and BMI of aripiprazole group decreased significantly compared with baseline (P0.05). There was no significant change in the metabolic parameters during the treatment. Fasting blood glucose, triglyceride, total cholesterol were significantly different from those in the control group (P 0.05). After 12 weeks of treatment, there were significant differences between the two groups. The total score of PANSS and the score of CGI-S in the two groups were significantly different before and after treatment (P 0.05), and there was no significant difference between the two groups (P 0.05). There was no significant difference between the three subscales of SQLS and baseline in aripiprazole group (P 0.05), but the scores of psychosocial subscale in control group were higher than those in baseline group (P 0.05). There was significant difference between the two groups. The adverse events of the two groups were mild or moderate, and most of them could be tolerated. Conclusion the treatment of olanzapine combined with low dose of aripiprazole 10 mg 路dl can significantly improve blood glucose in patients with stable schizophrenia. The metabolic parameters such as blood lipids had a tendency to lower body weight and the incidence of adverse events was lower. There was no significant effect on the quality of life of schizophrenic patients.
【作者单位】： 新乡医学院第二附属医院精神七科;
【基金】：国家自然科学基金(81371472) 河南省科技厅2012年科技发展计划(124200510019)
【分类号】：R749.3
【正文快照】： Effects of low-dose aripiprazole on metabolic profiles and quality of life ofschizophrenic patients with taking olanzapineZHAO Jing-yuan,LI Wen-qiang,GU Xiao-jing,AI Xiao-qing,HUA Ting-ting,L婬Lu-xian(The 7th Department of Psychiatry,the Second Affiliate，

本文编号：1405476